Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Iovance Biotherapeutics, Inc. (IOVA) had Stock-Based Compensation of $109.63M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$164.07M |
|
$-372.18M |
|
$124.00M |
|
$40.08M |
|
$559.35M |
|
$-395.28M |
|
$20.27M |
|
$-375.00M |
|
$-375.00M |
|
$-372.18M |
|
$-372.18M |
|
$-372.18M |
|
$-372.18M |
|
$-395.28M |
|
$-361.93M |
|
289.88M |
|
289.88M |
|
$-1.28 |
|
$-1.28 |
|
| Balance Sheet Financials | |
$457.02M |
|
$109.08M |
|
$453.41M |
|
$910.43M |
|
$122.34M |
|
$1.00M |
|
$77.68M |
|
$200.02M |
|
$710.40M |
|
$428.01M |
|
$710.40M |
|
305.25M |
|
| Cash Flow Statement Financials | |
$-352.98M |
|
$-96.41M |
|
$390.66M |
|
$181.32M |
|
$122.05M |
|
$-59.27M |
|
|
Stock-Based Compensation |
$109.63M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.74 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
24.43% |
|
-240.92% |
|
-240.92% |
|
-220.60% |
|
-228.56% |
|
-226.84% |
|
$-364.05M |
|
-- |
|
-- |
|
-- |
|
0.18 |
|
2.41 |
|
2.37 |
|
154.26 |
|
-52.39% |
|
-86.96% |
|
-40.88% |
|
-52.32% |
|
$2.33 |
|
$-1.26 |
|
$-1.22 |
|